Denmark· DK-28106617421
Pepaxti
A melphalan flufenamide product containing melphalanflufenamidhydrochlorid, registered in Denmark by Oncopeptides AB. The same ATC class is registered in 8 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Melphalan flufenamide is registered in 8 of 19 countries.
Countries holding a registration under ATC L01AA10 (melphalan flufenamide), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 5 of them publish a price we can compare per daily dose
Melphalan flufenamide · ATC L01AA10
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Melphalanflufenamidhydrochlorid
- Manufacturer
- Oncopeptides AB
- Country
- Denmark (DK)
- ATC code
- L01AA10
- ATC class
- Melphalan flufenamide
- Defined daily dose
- 1.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106617421
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
10 interactions on record for melphalan flufenamide.
Graded by severity as the source publishes them — 4 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Melphalan flufenamide · interactions on record
10 records
- 4 moderate
- 6 minor
Most severe, free to view
- IfosfamideL01AA06moderate
- DacarbazineL01AX04moderate
- CytarabineL01BC01moderate
- VinblastineL01CA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01AA10
Melphalan flufenamide, as other registers publish it.
- IcelandPepaxtiOncopeptides AB
- FinlandPepaxtiOncopeptides AB
- PolandPepaxtiOncopeptides AB (publ)
- CzechiaPEPAXTIOncopeptides AB, Stockholm
- BelgiumPepaxti 20 mgOncopeptides
- IrelandPepaxti 20 mg powder for concentrate for solution for infusionOncopeptides AB
- NetherlandsPepaxti 20 mg, poeder voor concentraat voor oplossing voor infusieOncopeptides AB
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b98489c7-63af-4db6-bb07-c1025c9e116a GET /v1/drugs/b98489c7-63af-4db6-bb07-c1025c9e116a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "pulver til koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "20 mg",
"auth_role": "MOD",
"dk_drugid": "28106617421",
"substance": "Melphalanflufenamidhydrochlorid",
"auth_procedure": "Central",
"in_medicinpriser": false,
"registration_date_serial": "44790"
}See everything about melphalan flufenamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.